Verona Pharma shares surge after results from latest study
13th Jan 2020 11:08
(Sharecast News) - Respiratory disease-focussed biopharmaceuticals company Verona Pharma announced positive top-line data from a four week, 416 patient phase 2b dose-ranging study evaluating nebulised ensifentrine or placebo as an add-on treatment to 'Spiriva Respimat', or tiotropium, which is a long acting anti-muscarinic bronchodilator, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Read moreVerona Pharma losses widen as it pours resources into ensifentrine
5th Nov 2019 11:29
(Sharecast News) - Biopharmaceutical company Verona Pharma updated the market on its operations and finances for the three and nine months ended 30 September on Tuesday, highlighting positive results from the second part of its phase 2 study of the dry powder inhaler formulation of 'ensifentrine' in chronic obstructive pulmonary disorder (COPD), delivered by handheld inhaler over one week of twice-daily treatment.
Read moreInland Homes snaps up 50% stake in Cheshunt Lakeside Development
29th Oct 2019 15:30
(Sharecast News) - Inland Homes on Tuesday acquired a 50% interest in joint-venture partner Cheshunt Lakeside Developments Limited that was held by CPC Group Limited.
Read moreVerona Pharma strengthens clinical team ahead of next round of trials
25th Jun 2019 15:31
(Sharecast News) - Respiratory-focussed biopharmaceutical company Verona Pharma announced two senior appointments to its clinical team on Tuesday.
Read moreDirector dealings: Piers Morgan's spouse ups stake in Verona Pharma
29th May 2019 16:23
(Sharecast News) - Verona Pharma revealed on Wednesday that chief financial officer Piers Morgan's wife Kayt Morgan had acquired 33,802 ordinary shares in the AIM-listed biotechnology outfit.
Read moreVerona Pharma announces next study of nebulised ensifentrine
7th May 2019 14:41
(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a phase 2b dose-ranging study evaluating nebulised ensifentrine (RPL554) added on to a long-acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) on Tuesday.
Read moreVerona Pharma gets another European patent on ensifentrine
9th Apr 2019 08:23
(Sharecast News) - Respiratory disease-focussed clinical stage biopharmaceutical company Verona Pharma announced on Tuesday that the European Patent Office had granted an additional key patent relating to its lead development candidate, 'ensifentrine'.
Read moreMonday broker round-up
4th Mar 2019 13:35
(Sharecast News) - RSA Insurance Group: JP Morgan downgrades to neutral with a target price of 610p.
Read moreVerona Pharma shares plunge on latest drug trial results
14th Jan 2019 08:48
(Sharecast News) - Verona Pharma shares were well into the red on Monday, after the clinical-stage biopharmaceutical company announced top-line data from its latest trial of RPL554, failing to reach its primary endpoint.
Read moreVerona Pharma granted WHO approval for Ensifentrine name
9th Jan 2019 15:44
(Sharecast News) - Clinical stage biopharmaceutical outfit Verona Pharma has been granted approval of the name Ensifentrine for its first-in-class, inhaled, dual inhibitor drug candidate RPL554 by the World Health Organisation.
Read moreVerona Pharma initiates Phase 2 study of RPL554
17th Dec 2018 14:22
(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a Phase 2 clinical trial to evaluate the pharmacokinetic (PK) profile, efficacy and safety of a dry powder inhaler (DPI) formulation of 'RPL554', in patients with moderate to severe chronic obstructive pulmonary disease (COPD), on Monday.
Read moreVerona Pharma turns in positive data from RPL554 trials
26th Oct 2018 11:46
(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma turned in some positive data from its pre-clinical and Phase 2a trials on its potential cystic fibrosis treatment RPL554.
Read moreVerona Pharma appoints sector veteran Morgan as CFO
26th Sep 2016 09:39
(ShareCast News) - AIM listed drug development company Verona Pharma appointed sector veteran Piers John Morgan as chief financial officer on Monday, as the company prepares for clinical trials for its flagship drug. Chartered accountant Morgan has 25 years' financial experience and was previously c
Read moreVerona Pharma makes progress on new respiratory drug
13th Sep 2016 12:04
(ShareCast News) - Verona Pharma, a UK based drug development company focused on first-in-class medicines to treat respiratory diseases, reported positive results on new drug "RPL554". The company's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulized maintenance tr
Read moreVerona Pharma secures funding for drug trial
20th Jun 2016 12:50
(ShareCast News) - Shares in AIM-listed Verona Pharma rallied on Monday as the drug development company it had successfully secured funding commitments to raise gross proceeds of around £44.7m through a conditional placing that was significantly oversubscribed. Net proceeds from the placing with new
Read more